Helen Cross, International League Against Epilepsy (ILAE): Presidential Update 2022

In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. ...

The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy.   In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New ...

Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...

Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. The impact and the constant care required for someone living with DS has on the patient and their family's quality of life can be huge. ...

Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...

Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...

touchNEUROLOGY caught up with the INS President, Prof. Marc Russo, to discuss the upcoming congress and what to expect. The International Neuromodulation Society (INS) is excited to announce the relaunch of the in-person INS 15th World Congress in Barcelona, Spain, ...

The efficacy and safety of fenfluramine, an anti-seizure medication, in patients with Lennox-Gastaut syndrome was assessed in phase 3 and open label extension studies (NCT03355209). Dr Kelly Knupp (Children’s Hospital Colorado, University of Colorado, CO, USA) discusses the findings of ...

Cenobamate is approved in the United States for focal-onset seizures (partial-onset seizures) in adults both as adjunctive and monotherapy. In the EU, cenobamate is approved as adjunctive therapy for focal-onset seizures with or without secondary generalization for adult patients who ...

The World Congress on Controversies in Neurology (CONy) provides a platform for international experts to discuss and compare experience in many areas of neurology and in treatment of neurological diseases, thus closing the gap between the expansion of knowledge and ...

touchNEUROLOGY met with Professor Mary Koenig (McGovern Medical School, UTHealth, Houston, TX, USA) to discuss the efficacy and safety findings from the phase 2 clinical study investigating oral ganaxolone for the treatment of tuberous sclerosis complex (NCT04285346). The abstract 'Phase 2 Open-label ...

It was a great pleasure to meet with both Dr Monica Ferrer Socorro (NYU Langone Health, New York City, NY, USA) and Prof. Jacqueline French (NYU Grossman School of Medicine, New York City, NY, USA) to discuss a retrospective analysis ...